NEW SHAREHOLDER LOCK-UP EXTENSION ANNOUNCED
EUROAPI has recently disclosed that its primary stakeholders, Sanofi and EPIC Bpifrance, have decided to extend their lock-up period until December 18, 2026. This extension is set amidst several customary exceptions and aims to fortify the stability of EUROAPI's shareholding as the company progresses with its FOCUS-27 plan. This announcement is pivotal in reinforcing investor confidence, especially as the market undergoes fluctuations.
BRAKING: BUSINESS FORECAST AND STRATEGY
In light of recent developments, EUROAPI has unveiled its business forecast for the upcoming period. While the overall business climate has deteriorated, it still remains dedicated to maintaining its operational effectiveness. The anticipated core EBITDA margin for the financial year 2025 is expected to stay between 7% and 9%. This projection is a testament to the company's commitment to stringent cost reduction strategies and effective resource management.
Current Market Challenges
The company projects a mid-single-digit decrease in Net Sales for the full year of 2025 on a comparable basis, a notable adjustment from the previously expected low-single-digit drop. These projections reflect a comprehensive assessment of the increasing market pressures faced by EUROAPI, driving the need for adaptive strategies to navigate through these challenges.
FOCUS-27 PLAN UPDATE
The implementation of the FOCUS-27 plan is witnessing steady progress, bolstered by ongoing advancements in cost efficiencies across the organization. EUROAPI is actively monitoring the business environment's evolution to discern its implications on their operational strategies and commitments.
Future Updates and Financial Agenda
EUROAPI intends to provide further insights and updates during its earnings release on March 3, 2026, which will coincide with the announcement of the full year 2025 results. The financial schedule will also include the annual general meeting set for May 27, 2026, and mid-year results on July 28, 2026.
ABOUT EUROAPI
EUROAPI is on a mission to transform how active ingredient solutions are crafted to cater sustainably to global customer and patient needs. Standing as a leader in active pharmaceutical ingredients, it boasts an extensive portfolio of roughly 200 products and continues developing innovatives through their Contract Development and Manufacturing Organization (CDMO) services. With a workforce of approximately 3,270 individuals, EUROAPI's commitment includes maintaining stringent quality in API manufacturing across five European sites. The company proudly caters to customers in over 80 countries, ensuring consistent access to essential therapies.
CONTACT FOR MEDIA AND INVESTORS
For Media Inquiries:
Laurence Bollack
Telephone: +33 (0)6 81 86 80 19
Email: mr@euroapi.com
Investor Relations Contacts:
Sophie Palliez-Capian
Telephone: +33 (0)6 87 89 33 51
Email: Sophie.palliez@euroapi.com
Léa Massonneau
Telephone: +33 (0)7 60 32 29 50
Email: lea.massonneau@euroapi.com
Frequently Asked Questions
What is the recent announcement by EUROAPI about shareholders?
EUROAPI announced an extension of the lock-up period among major shareholders Sanofi and EPIC Bpifrance until December 18, 2026.
What is the expected change in sales for EUROAPI in 2025?
The company expects to see a mid-single-digit decrease in Net Sales for the full year 2025, which is an adjustment from earlier projections.
What are the core EBITDA margin expectations for 2025?
The core EBITDA margin is anticipated to reside within the range of 7% to 9% for the fiscal year 2025.
When will EUROAPI release its financial results?
The company plans to share its full year 2025 results on March 3, 2026.
What role does EUROAPI play in the pharmaceutical industry?
EUROAPI focuses on providing active pharmaceutical ingredients and aims to sustainably meet the needs of customers and patients globally.
